253 related articles for article (PubMed ID: 26263974)
1. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
Simeon V; Todoerti K; La Rocca F; Caivano A; Trino S; Lionetti M; Agnelli L; De Luca L; Laurenzana I; Neri A; Musto P
Int J Mol Sci; 2015 Jul; 16(8):17514-34. PubMed ID: 26263974
[TBL] [Abstract][Full Text] [Related]
2. Primary plasma cell leukemia in the era of new drugs: has something changed?
Musto P; Pagano L; Petrucci MT; Morabito F; Caravita T; Di Raimondo F; Baldini L; Tosi P; Bringhen S; Offidani M; Omede' P; Neri A; D'Auria F; Bochicchio GB; Cavo M; Boccadoro M; Palumbo A
Crit Rev Oncol Hematol; 2012 May; 82(2):141-9. PubMed ID: 21719304
[TBL] [Abstract][Full Text] [Related]
3. Primary plasma cell leukemia 2.0: advances in biology and clinical management.
Neri A; Todoerti K; Lionetti M; Simeon V; Barbieri M; Nozza F; Vona G; Pompa A; Baldini L; Musto P
Expert Rev Hematol; 2016 Nov; 9(11):1063-1073. PubMed ID: 27759436
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.
Nishihori T; Abu Kar SM; Baz R; Alsina M; Harousseau JL; Kharfan-Dabaja MA
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1144-51. PubMed ID: 23416092
[TBL] [Abstract][Full Text] [Related]
5. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
6. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report.
Wöhrer S; Ackermann J; Baldia C; Seidl S; Raderer M; Simonitsch I; Drach J
Hematol J; 2004; 5(4):361-3. PubMed ID: 15297854
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.
Todoerti K; Agnelli L; Fabris S; Lionetti M; Tuana G; Mosca L; Lombardi L; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Omede' P; Tassone P; Boccadoro M; Palumbo A; Neri A; Musto P
Clin Cancer Res; 2013 Jun; 19(12):3247-58. PubMed ID: 23599371
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
Wang H; Zhou H; Zhang Z; Geng C; Chen W
Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
[TBL] [Abstract][Full Text] [Related]
9. The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell Leukemia.
Jurczyszyn A; Olszewska-Szopa M; Vesole DH
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):188-193. PubMed ID: 36593169
[TBL] [Abstract][Full Text] [Related]
10. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
[TBL] [Abstract][Full Text] [Related]
11. Global methylation patterns in primary plasma cell leukemia.
Todoerti K; Calice G; Trino S; Simeon V; Lionetti M; Manzoni M; Fabris S; Barbieri M; Pompa A; Baldini L; Bollati V; Zoppoli P; Neri A; Musto P
Leuk Res; 2018 Oct; 73():95-102. PubMed ID: 30257227
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles.
Mosca L; Musto P; Todoerti K; Barbieri M; Agnelli L; Fabris S; Tuana G; Lionetti M; Bonaparte E; Sirchia SM; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Caravita T; Omedè P; Boccadoro M; Palumbo A; Neri A
Am J Hematol; 2013 Jan; 88(1):16-23. PubMed ID: 23044976
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
[TBL] [Abstract][Full Text] [Related]
14. Plasma cell leukemia: a rare condition.
Jiménez-Zepeda VH; Domínguez VJ
Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.
Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A
Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
Davidsen ML; Dalhoff K; Schmiegelow K
J Pediatr Hematol Oncol; 2008 Nov; 30(11):831-49. PubMed ID: 18989161
[TBL] [Abstract][Full Text] [Related]
17. Primary plasma cell leukemia presenting as a thoracic mass.
Igala M; Bopaka RG; Khtabi W; Benchekroun S; Quessar A
Pan Afr Med J; 2014; 19():39. PubMed ID: 25667701
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
19. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
Hofste Op Bruinink D; Kuiper R; van Duin M; Cupedo T; van der Velden VHJ; Hoogenboezem R; van der Holt B; Beverloo HB; Valent ET; Vermeulen M; Gay F; Broijl A; Avet-Loiseau H; Munshi NC; Musto P; Moreau P; Zweegman S; van de Donk NWCJ; Sonneveld P
J Clin Oncol; 2022 Sep; 40(27):3132-3150. PubMed ID: 35357885
[TBL] [Abstract][Full Text] [Related]
20. Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.
Gowin K; Skerget S; Keats JJ; Mikhael J; Cowan AJ
Leuk Res; 2021 Dec; 111():106687. PubMed ID: 34425325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
